clinical

Why FORZE Reload and Alliance Dominate Tomorrow’s CS2 Showdowns

Why FORZE Reload and Alliance Dominate Tomorrow’s CS2 Showdowns

Published: Nov 5, 2025 Selection 1: FORZE Reload’s Relentless Assault on SPARTA @-175 At 12:00 UTC in the NODWIN Clutch Series #2, FORZE Reload faces...

LoL Worlds 2025 Grand Final Preview: T1 vs KT Rolster – The Ultimate Telecom War

LoL Worlds 2025 Grand Final Preview: T1 vs KT Rolster – The Ultimate Telecom War

Published: Nov 3, 2025 In a clash that feels scripted for the ages, T1 and KT Rolster will battle for the Summoner’s Cup in the...

Danganronpa-Inspired Horror Kumitantei Partners with Akupara Games for 1989 Mystery Thriller

Danganronpa-Inspired Horror Kumitantei Partners with Akupara Games for 1989 Mystery Thriller

Publisher Akupara Games has officially announced a new partnership with developer Mango Factory for their upcoming murder-mystery horror title, Kumitantei: Old-School Slaughter. Drawing heavy inspiration...

China’s TES Rising to Burn T1’s Legacy in Worlds SF2

China’s TES Rising to Burn T1’s Legacy in Worlds SF2

Published: Oct 31, 2025 The Mercedes-Benz Arena in Shanghai is set to erupt on November 2 as Top Esports clash with T1 in LoL Worlds...

Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput

Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput

Ultrahigh-Resolution Scanning Electron Microscope SU9600 TOKYO, October 31, 2025 – (JCN Newswire) – Hitachi High-Tech Corporation (“Hitachi High-Tech”), has launched the Ultrahigh-Resolution Scanning Electron Microscope...

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus

HONG KONG, Oct 31, 2025 – (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic...

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China

SHENZHEN, Oct 30, 2025 – (ACN Newswire) – China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an...

Top 5 Picks for October 30: U. De Chile vs Lanus and more!

Top 5 Picks for October 30: U. De Chile vs Lanus and more!

We’re expecting an action-packed, profitable day! Check out these cool highlights on Zcode’s board that you won’t want to miss. The excitement is palpable as...

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

HONG KONG, Oct 30, 2025 – (ACN Newswire) – Everest Medicines (HKEX:1952.HK) today announced that it has acquired an exclusive license with Visara, Inc. (“Visara”),...

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

TOKYO and RAHWAY, NJ, Oct. 29, 2025 – (JCN Newswire) – Eisai (Headquarters: Tokyo, CEO: Haruo Naito) and Merck & Co., Inc., Rahway, NJ, USA...

WELCOME!

Please, verify your age to enter.

By entering this site, you are agreeing to the Terms of Use and Privacy Policy.